| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4846635
Max Phase: Preclinical
Molecular Formula: C19H25FN4O3S
Molecular Weight: 408.50
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: COCCCS(=O)(=O)Nc1ccc(-c2ccc(F)cc2N2CCCCC2)nn1
Standard InChI: InChI=1S/C19H25FN4O3S/c1-27-12-5-13-28(25,26)23-19-9-8-17(21-22-19)16-7-6-15(20)14-18(16)24-10-3-2-4-11-24/h6-9,14H,2-5,10-13H2,1H3,(H,22,23)
Standard InChI Key: FWKJYEYQEXKXJB-UHFFFAOYSA-N
Associated Targets(Human)
Kynurenine 3-monooxygenase 379 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 408.50 | Molecular Weight (Monoisotopic): 408.1631 | AlogP: 3.05 | #Rotatable Bonds: 8 |
| Polar Surface Area: 84.42 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
| #RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 7.01 | CX Basic pKa: 2.71 | CX LogP: 2.04 | CX LogD: 1.61 |
| Aromatic Rings: 2 | Heavy Atoms: 28 | QED Weighted: 0.68 | Np Likeness Score: -1.74 |
References
| 1. Tsuboi K, Kimura H, Nakatsuji Y, Kassai M, Deai Y, Isobe Y.. (2021) Discovery of N-(6-(5-fluoro-2-(piperidin-1-yl)phenyl)pyridazin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)methanesulfonamide as a brain-permeable and metabolically stable kynurenine monooxygenase inhibitor., 44 [PMID:34015507] [10.1016/j.bmcl.2021.128115] |
Source
Source(1):